Stereotactic Ablative radiation therapy (SABR) for cardiac arrhythmia: A new therapeutic option?

• Published in: Radiologia medica Vol. 126; no. 1; pp. 155 - 162
• Main Authors: Fiorentino, Alba, Gregucci, Fabiana, Bonaparte, Ilaria, Vitulano, Nicola, Surgo, Alessia, Mazzola, Rosario, Di Monaco, Antonio, Carbonara, Roberta, Alongi, Filippo, Langialonga, Tommaso, Grimaldi, Massimo
• Format: Journal Article
• Language: English
• Published: Milan Springer Milan 01.01.2021; Springer Nature B.V
• Subjects: Ablation; Arrhythmia; Arrhythmias, Cardiac - radiotherapy; Cardiac arrhythmia; Diagnostic Radiology; Humans; Imaging; Interventional Radiology; Magnetic resonance; Medicine; Medicine & Public Health; Neuroradiology; Radiation therapy; Radiology; Radiosurgery - methods; Radiotherapy; Reliability analysis; Ultrasound; Cardiac arrhythmia; Radiotherapy; SRS; Cardiac ablation; Radiosurgery
• ISSN: 0033-8362; 1826-6983
• DOI: 10.1007/s11547-020-01218-7

Aim Stereotactic ablative radiation therapy (SABR) is used in non-oncologic indications, recently even for cardiac arrhythmias. Thus, aim of this analysis is to review preclinical, early clinical evidences and future direction of the latter new treatment approach. Method A collection of available data regarding SABR and cardiac arrhythmias was made, by Pubmed research and 2 independent researchers, including preclinical and clinical data. A review of ongoing trials was conducted on ClinicalTrials.gov. Results Preclinical research conducted in animal models showed that a safe and effective noninvasive treatment approach for cardiac arrhythmias could be represented by SABR with a median time of response around 2–3 months. The treatment dose plays a crucial role: the atrioventricular node would seem more radiosensitive than the other cardiac electric zones. Clinical data, such as published case series, case reports and early prospective studies, have already suggested the feasibility, efficacy and safety of SABR (25 Gy in one session) for refractory ventricular arrhythmias. Conclusion Considering the ongoing trials of SABR and new technological improvements in radiotherapy (e.g. hybrid magnetic resonance) and in arrhythmias noninvasive mapping systems, the future analyses will improve the reliability of those preliminary results.